Future oncology最新文献_第6页

A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study). 在不应接受铂类化疗的非小细胞肺癌患者中，atezolizumab与单药化疗的比较（IPSOS研究）。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-20 DOI: 10.1080/14796694.2025.2500915

Siow Ming Lee, Christian Schulz, Anne-Marie Baird, Kumar Prabhash, Dariusz Kowalski, Aleksandra Szczesna, Baohui Han, Achim Rittmeyer, Toby Talbot, David Vicente, Raffaele Califano, Diego Cortinovis, Anh Tuan Le, Dingzhi Huang, Geoffrey Liu, Federico Cappuzzo, Jessica Reyes Contreras, Martin Reck, Ramon Palmero, Milena Perez Mak, Youyou Hu, Stefanie Morris, Monika Kaul, Patricia Corey-Lisle, Barbara Gitlitz, Solange Peters

引用次数: 0

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer. selpercatinib和pralsetinib在RET融合阳性非小细胞肺癌中的匹配调整间接比较。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-06-03 DOI: 10.1080/14796694.2025.2508132

Maximilian Hochmair, Urpo Kiiskinen, Yulia D'yachkova, Tarun Puri, Xuwen Wang, Sorrel Wolowacz, Adrian Vickers, Ernest Nadal

{"title":"Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer.","authors":"Maximilian Hochmair, Urpo Kiiskinen, Yulia D'yachkova, Tarun Puri, Xuwen Wang, Sorrel Wolowacz, Adrian Vickers, Ernest Nadal","doi":"10.1080/14796694.2025.2508132","DOIUrl":"10.1080/14796694.2025.2508132","url":null,"abstract":"Aims: Selpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methods: Efficacy and safety were compared using matching-adjusted indirect comparison.Results: Median progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade ≥ 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.Conclusion: Outcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade ≥ 3 TRAEs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1867-1878"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer. MARIPOSA-2: amivantamab-化疗联合或不联合lazertinib治疗非小细胞肺癌。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-06 DOI: 10.1080/14796694.2025.2492456

Antonio Passaro, Alexis B Cortot, Ryan D Gentzler, Karen L Reckamp, Sujay Shah, William Nassib William, Byoung Chul Cho

引用次数: 0

Are we doing enough to treat cancer pain? The urgent need for action in oncology practice. 我们在治疗癌痛方面做得够不够？迫切需要在肿瘤实践中采取行动。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-07 DOI: 10.1080/14796694.2025.2501522

Massimo Aglietta, Berardi Rossana, Guido Biasco, Paolo Bossi, Marta Gentili, Luca Giacomelli, Gaetano Lanzetta, Franco Marinangeli, Giuseppe Tonini, Renato Vellucci

引用次数: 0

Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China. 厄达非替尼作为晚期转移性尿路上皮癌二线治疗的经济评价：来自美国的真实数据和来自中国的前瞻性分析

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-10 DOI: 10.1080/14796694.2025.2504321

Andong Li, Meiyu Wu, Ouyang Xie, Heng Xiang, Kehui Meng, Xiaomin Wan

{"title":"Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China.","authors":"Andong Li, Meiyu Wu, Ouyang Xie, Heng Xiang, Kehui Meng, Xiaomin Wan","doi":"10.1080/14796694.2025.2504321","DOIUrl":"10.1080/14796694.2025.2504321","url":null,"abstract":"Background and objective: Metastatic urothelial carcinoma (mUC) is challenging to treat, with 37% of patients failing first-line therapy. Effective second-line treatments, like Erdafitinib, are crucial. This study evaluates the cost-effectiveness of Erdafitinib as a second-line treatment for mUC from US and Chinese payer perspectives.Methods: A Markov model was developed to project costs, life years, and quality-adjusted life years (QALYs) over lifetime. Data were collected from December 2023 to December 2024 for up-to-date estimates and were obtained from literature, health databases, and clinical trials.. The model was run to project long-term outcomes for both the United States and China.Results: In the United States, Erdafitinib provides an additional 0.467 QALYs at a cost of $238,294.2 per QALY, which exceeds the $150,000 per QALY willingness-to-pay threshold. For China, when the cost of Erdafitinib is below $6.9 or $14 per milligram, there is a 90% probability that its incremental cost-effectiveness ratio will be below $38,223 or $84,966 per QALY, respectively.Conclusions: From the perspective of U.S. payers, Erdafitinib as a second-line treatment for mUC is not cost-effective. From the perspective of China, the cost-effectiveness of Erdafitinib is highly sensitive to its price, which could provide a reference for healthcare reimbursement negotiations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1919-1927"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment. TURALIO®风险评估和缓解策略（tREMS）项目：5年回顾性肝脏安全评估。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-29 DOI: 10.1080/14796694.2025.2509409

Abdul Waheed Rajper, Charles Dharmani, Lalitha Chilakapati, Oluwatosin Fofah, Margaret J Wooddell

{"title":"TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment.","authors":"Abdul Waheed Rajper, Charles Dharmani, Lalitha Chilakapati, Oluwatosin Fofah, Margaret J Wooddell","doi":"10.1080/14796694.2025.2509409","DOIUrl":"10.1080/14796694.2025.2509409","url":null,"abstract":"Aims: To assess hepatic safety data of pexidartinib in adult patients with tenosynovial giant cell tumor (TGCT) from the retrospective 5-year evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program.Patients & methods: We analyzed data collected from healthcare professionals, patients, pharmacies, and distributors who participated in the tREMS Program from August 2019 to June 2024.Results: For the current reporting period, June 2022 to June 2024, of the 524 patients enrolled in the tREMS with ≥ 1 dispense of pexidartinib, 24 (4.6%) had adverse events or laboratory abnormalities suggestive of serious and potentially fatal liver injury, with a total of 45/735 (6.1%) patients over 5 years. One (0.2%) patient in the current period had confirmed vanishing bile duct syndrome (VBDS) and was recovering at last follow-up. Another patient from the previous reporting period had unconfirmed VBDS and was alive with unknown recovery status at last follow-up. For the current reporting period and cumulative 5-year tREMS assessment, the reported frequency and pattern of liver injury were consistent with the phase 3 ENLIVEN trial.Conclusions: The tREMS Program effectively mitigates the risk of hepatotoxicity through careful monitoring and early intervention. Pexidartinib remains a viable treatment option for TGCT when managed according to recommended guidelines.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1859-1865"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain language summary. 膀胱内注射nadofaragene firadenovec基因治疗bcg无反应的非肌肉侵袭性膀胱癌，一项5年随访研究：简单的语言总结

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-21 DOI: 10.1080/14796694.2025.2493041

Betty Wang, Christopher Weight, Adam Calaway, Robert Abouassaly, Andres Correa, Rebecca Campbell, Devika Nandwana, Fran Curtis, Gennady Bratslavsky, Joe Jacob, Laura Bukavina

引用次数: 0

Amino acid deprivation vs. mainstream cancer therapeutics: exploring the potential and limitations. 氨基酸剥夺与主流癌症治疗：探索潜力和局限性。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-19 DOI: 10.1080/14796694.2025.2508134

Abhay H Pande, Yenisetti Rajendra Prasad, J Anakha

引用次数: 0

A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. POLARIS的简单语言总结：一项研究，观察不同剂量的恩可非尼加比尼美替尼治疗BRAF v600突变黑色素瘤伴脑转移患者。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI: 10.1080/14796694.2025.2495540

Alexander M Menzies, Georgina V Long, Amiee Kohn, Hussein Tawbi, Jeffrey Webe, Keith Flaherty, Grant A McArthur, Paolo A Ascierto, Yanina Pfluger, Karl Lewis, Katy K Tsai, Omid Hamid, Hans Prenen, Luis Fein, Erjian Wang, Carolin Guenzel, Fan Zhang, Joseph F Kleh, Alessandra di Pietro, Michael A Davies

引用次数: 0

Busulfan-cyclophosphamide vs fludarabine-busulfan for allogeneic transplant in acute myeloid leukemia. 布磺胺-环磷酰胺vs氟达拉滨-布磺胺用于急性髓系白血病同种异体移植。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-28 DOI: 10.1080/14796694.2025.2507563

Ben Abdeljelil N, Kanoun R Y, Mekni S, Turki I, Ben Yaiche I, Ouerghi R, Belloumi D, Torjemane L, Ladeb S, Ben Othman T

{"title":"Busulfan-cyclophosphamide vs fludarabine-busulfan for allogeneic transplant in acute myeloid leukemia.","authors":"Ben Abdeljelil N, Kanoun R Y, Mekni S, Turki I, Ben Yaiche I, Ouerghi R, Belloumi D, Torjemane L, Ladeb S, Ben Othman T","doi":"10.1080/14796694.2025.2507563","DOIUrl":"10.1080/14796694.2025.2507563","url":null,"abstract":"Background: Busulfan and cyclophosphamide (BuCy) is the standard myeloablative conditioning regimen for patients with acute myeloblastic leukemia (AML) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Fludarabine and busulfan (FluBu) conditioning seems to have similar efficacy with less toxicity.Aims and methods: Descriptive retrospective study conducted on patients with AML who underwent geno-identical allo-HSCT between January 2011 and December 2022. Patients received a myeloablative conditioning with either BuCy2 orFluBu4. The objective was to compare the efficacy and safety of this regimens.Results: A total of 113 adult patients were included. Conditioning regimen was BuCy2 in 81% of patients (n = 92) and FluBu4 in 19% of patients (n = 21). The 3-year estimated overall survival and event-free survival were 65% vs 81% (p = 0.19) and 58% vs 76% (p = 0.18) in BuCy2 and FluBu4 regimens, respectively. GVHD-Relapse Free Survival was better in FluBu4 group compared to BuCy2 group (28% vs 41%, p = 0.03). The Cumulative incidence of relapse and non-relapse mortality were 38% vs 14% (p = 0.17) and 15% vs 10% (p = 0.57) in BuCy2 and FluBu4, respectively. Both regimens yield comparable toxicities.Conclusion: Myeloablative FluBu4 conditioning appeared to achieve clinical outcomes similar to BuCy2 and may be considered as a possible alternative for patients at high risk of NRM.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1887-1894"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0